Benitec Biopharma Stock Forum

$Benitec Biopharma (BNTC.US)$
The latest clinical and financial update from Benitec Biopharma presents a compelling narrative in the rare disease space. The BB-301 gene therapy program continues to demonstrate encouraging progress with five subjects now safely treated in the Phase 1b/2a trial for Oculopharyngeal Muscular Dystrophy (OPMD).
The interim data is particularly noteworthy as it shows durable improvements in both key measures of dysphagia: Total Pharyngeal Resi...

$Benitec Biopharma (BNTC.US)$
Breakthrough in Muscular Dystrophy Treatment: Benitec's Clinical Trial Delivers Promising Results Amid Q2 Report

$Benitec Biopharma (BNTC.US)$
The acceptance of a late-breaking oral presentation at the prestigious MDA conference carries significant weight in the clinical research community. Late-breaking abstracts are typically reserved for groundbreaking developments that emerge after standard submission deadlines, suggesting the data's novelty and potential importance.
The planned presentation of interim data from three subjects is particularly noteworthy in the context of rare ...

$Benitec Biopharma (BNTC.US)$
Clinical Breakthrough: Benitec's Novel Muscular Dystrophy Therapy Demonstrates Remarkable Swallowing Improvements

$Benitec Biopharma (BNTC.US)$ One is from today! And im including the one from mid November just so you got a idea of how many they been buying! Hehehe

$Benitec Biopharma (BNTC.US)$
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society
Benitec Biopharma (NASDAQ: BNTC) reported positive interim data from its Phase 1b/2a study of BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD). Two subjects treated with the low-dose BB-301 showed durable, clinically meaningful improvements in swallowing at 9 and 6 months post-t...

$Benitec Biopharma (BNTC.US)$ Benitec Biopharma Inc: Bb-301 Has Been Granted Orphan Drug Designation by US FDA and EMA Committee for Orphan Medicinal Products (Comp)

$Benitec Biopharma (BNTC.US)$ phase 1 :X